Pralatrexate: an emerging new agent with activity in T-cell lymphomas
OA O'Connor - Current opinion in oncology, 2006 - journals.lww.com
OA O'Connor
Current opinion in oncology, 2006•journals.lww.comPralatrexate is an antifolate designed to be internalized more rapidly than other traditional
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early
phase I and II studies have shown marked activity across many poor-risk subtypes of TCL.
Future studies are directed towards understanding the pharmacokinetic features of the drug,
and expanding the population of patients with TCL and B-cell lymphomas.
antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early
phase I and II studies have shown marked activity across many poor-risk subtypes of TCL.
Future studies are directed towards understanding the pharmacokinetic features of the drug,
and expanding the population of patients with TCL and B-cell lymphomas.
Summary
Pralatrexate is an antifolate designed to be internalized more rapidly than other traditional antifolates. Preclinical studies have demonstrated its superiority to methotrexate, and early phase I and II studies have shown marked activity across many poor-risk subtypes of TCL. Future studies are directed towards understanding the pharmacokinetic features of the drug, and expanding the population of patients with TCL and B-cell lymphomas.
Lippincott Williams & Wilkins以上显示的是最相近的搜索结果。 查看全部搜索结果